Recent information from the biotech market indicates notable activities around KeyCorp (KEY). Activist HoldCo Asset Management has taken a $140M stake in the company and is calling for the dismissal of the CEO and advocating for increased share buybacks. This radical investor action has shifted the narrative around KeyCorp's investment profile and is seen to foster change in KeyCorp's strategic approach. KeyCorp's recent earnings have exceeded projections, although their momentum has cooled despite growth. Invesco Ltd., Schroder Investment Management Group, and Norges Bank have all increased their shares in the company. The financial market is presenting mixed views around KeyCorp's share value, with Jefferies Financial Group raising their price target to $19.00 while TD Cowen maintains a hold rating with a reduced price target. Some question KeyCorp's attractiveness following multiple years of strong share price gains. Amid these shifts, KeyCorp has declared quarterly cash dividends and lowered its prime lending rate. Moving forward, KeyCorp is advised to maintain a no-acquisition policy to focus on internal growth and improvement.
Keycorp KEY News Analytics from Tue, 22 Apr 2025 07:00:00 GMT to Sat, 06 Dec 2025 15:36:16 GMT -
Rating 0
- Innovation -5
- Information 5
- Rumor -3
